T he prevalence of obesity and associated morbidities is increasing worldwide, 1 making obesity the second most preventable cause of death in the United States.
T he prevalence of obesity and associated morbidities is increasing worldwide, 1 making obesity the second most preventable cause of death in the United States. 2, 3 The association between obesity and insulin resistance has been known for ≥4 decades 4 ; overweight and obese subjects have a greater risk of developing insulin resistance and, therefore, of developing diabetes mellitus and other complications of obesity. However, not all obese subjects develop insulin resistance, 5 and this study explored the possibility that the presence of sympathetic activation is associated with insulin resistance in obese individuals and contributes to this phenomenon.
Obesity is also associated with an increase in sympathetic activity. Fat mass, and more specifically visceral fat, is positively correlated with muscle sympathetic nerve activity (MSNA), which is arguably the most accurate measurement of central sympathetic outflow coupled to blood pressure (BP) regulation. 6 The sympathetic nervous system plays an important role in metabolic regulation, influencing key processes, such as glucose and lipid metabolism, and all components of daily energy expenditure, including resting metabolic rate, the thermic effect of food and energy expenditure from physical activity. Furthermore, increased sympathetic activity has been associated with the development of insulin resistance, 7 and activation of the sympathetic nervous system with lower body negative pressure acutely decreases forearm muscle glucose uptake in healthy subjects. 8 Animal studies suggest that sympathetic activation contributes to insulin resistance. 9 In humans, there is an inverse relationship between insulin sensitivity and whole-body norepinephrine spillover in obese individuals, and MSNA is higher in those with insulin resistance when compared with those who are insulin sensitive. 10 Not all studies, however, have found that sympathetic activity is associated with decreased insulin sensitivity. 11, 12 Furthermore, a direct causal link between the sympathetic nervous system and insulin sensitivity has not been established in obesity.
We hypothesized that sympathetic activation associated with obesity contributes to insulin resistance. To test this hypothesis, we used the hyperinsulinemic euglycemic clamp to measure insulin sensitivity in obese subjects suspected to have both increased sympathetic activity and insulin resistance. We studied them under intact conditions and after acute autonomic blockade induced by the ganglionic blocker trimethaphan. If our hypothesis is correct, we would expect that autonomic blockade would result in improved insulin sensitivity, and that this effect would be apparent in obese subjects with increased sympathetic activity and insulin resistance.
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Methods

Subjects
The study was reviewed and approved by the Vanderbilt University Institutional Review Board, and written informed consent was obtained from each subject before initiating the study. Obese volunteers were recruited from the Vanderbilt University Clinical Research Center volunteer database and Research Match. 13 Subjects 18 to 60 years old of either sex with a body mass index between 30 and 45 kg/m 2 were considered eligible for the study. Current smokers, subjects with diabetes mellitus, and pregnant women were excluded. Hypertension was not a criterion for exclusion but all medications, including antihypertensives, were withdrawn ≥7 days before each study day with the exception of oral contraceptives. Subjects abstained from caffeine and other substances that are known to have an effect on the autonomic nervous system for ≥72 hours before testing. Screening included clinical examination, ECG, urinalysis, and routine laboratory testing (ie, blood count and chemistry).
Study Design
Insulin sensitivity was assessed on 2 separate days, 1 month apart, using a randomized single-blind crossover design with a computergenerated randomization code. A hyperinsulinemic euglycemic clamp was performed on both occasions as previously described 14 using identical instrumentation: once with intact autonomic function and once during autonomic blockade ( Figure 1 ). Subjects were classified as insulin resistant or sensitive based on the glucose infusion rate on the intact day. MSNA was measured on a separate occasion, ≥1 week after either insulin clamp.
Study Procedures
Hyperinsulinemic Euglycemic Clamp
Participants were admitted to the Vanderbilt Clinical Research Center the evening before the study and given a standard meal. After an overnight fast, subjects were studied the next morning in the supine position. A catheter was inserted into a forearm vein for drug infusion. A second catheter was inserted into a contralateral superficial forearm or hand vein, which was heated to obtain arterialized blood samples. 15 A primed continuous insulin infusion (4 mU/kg per minute for 8 minutes, then 2 mU/kg per minute) was maintained for 2 hours. Plasma glucose levels were measured every 5 minutes for the duration of the study (120 minutes). Potassium chloride was infused at 10 mmol/h to prevent insulin-induced hypokalemia. Plasma samples were taken at baseline and at minute 105 (middle of the last 30 minutes of the clamp). Euglycemia (4.99-5.55 mmol/L or 90-100 mg/dL) was maintained by a variable infusion of 20% dextrose, and the glucose infusion rate during minutes 90 to 120 of the clamp was used as a measure of insulin sensitivity (Figure 1 ).
Autonomic Blockade Study Day
Continuous BP was measured through the volume clamp method (BMEYE, Nexfin; Edwards Lifesciences) and also every 5 minutes with an automated oscillometric brachial cuff (Vital-Guard 450C; Ivy Biomedical Systems). Heart rate (HR) was determined with continuous ECG monitoring. Thirty minutes after the insulin infusion was started, intravenous infusion of trimethaphan was started and maintained throughout the study at a dose (4 mg/min) shown to induce complete autonomic blockade. 16 Insulin induces nitric oxide (NO)-mediated vasodilation and this will lower BP in the presence of autonomic blockade. We prevented a drop in BP using a variable infusion rate of the NO synthase inhibitor N-monomethyl-L-arginine, started 10 minutes before trimethaphan at a dose of 50 μg/kg per minute and adjusted to restore the individual subjects' baseline BP (up to a maximum systolic BP of 140 mm Hg in hypertensive subjects). Similar BP levels were achieved on both days at baseline and at the end of the hyperinsulinemic clamp ( Table 2 ).
Intact Autonomic Study Day
All procedures were identical to the blocked study day; normal saline was infused instead of trimethaphan and N-monomethyl-L-arginine, at a rate of 48 mL/h, to mimic the rate of trimethaphan infused on the autonomic blockade day.
Muscle Sympathetic Nerve Activity
Resting MSNA was measured as previously described. 17 MSNA bursts were identified after filtering the integrated signal, and artifacts were eliminated using an automated detection algorithm. MSNA bursts were accepted if the signal:noise ratio was >2:1, and synchronization to a previous cardiac event was found in an interval between 1.2 and 1.6 s. All detections were visually verified.
Spectral Analysis
ECG and BP were digitized with 14-bit resolution and 500-Hz sample frequency, recorded (WINDAQ data acquisition system, DATAQ), and analyzed using a customized analysis program written in PV-Wave by one of the authors (A.D.). Spectral analysis was performed as previously described 18 and according to Task Force recommendations. 19 Linear trends were removed and power spectral density was estimated with the fast fourier transform-based Welch algorithm using segments of 256 data points with 50% overlapping and Hanning window. 20 The power in the frequency range of low frequencies (0.04-0.15 Hz) and high frequencies (0.15-0.40 Hz) were calculated. Abolition of HR rate and BP variability was used to document autonomic blockade. In addition, low-frequency variability of systolic BP (LF SYS ) was used as an indirect measure of sympathetic modulation, 21 whereas highfrequency variability of HR (HF RRI ) was used as an indirect measure of cardiac parasympathetic modulation.
22,23
Analytic Measurements
Screening glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein levels were measured by the Vanderbilt University Medical Center Clinical Laboratory. During the clamps, plasma glucose was measured in duplicate every 5 minutes using a YSI 2300 STAT plus device (YSI Inc Life Sciences, Yellow Spring, OH). Plasma insulin, glucagon, and leptin were measured by double-antibody/PEG RIA by Vanderbilt Hormone Assay Core Laboratory. Plasma adiponectin and resistin were measured using Lincoplex Multiplex Immunoassay (Millipore). Free fatty acids were measured using an enzymatic assay (HR series NEFA-HR(2) assay; Wako Diagnostics, Richmond, VA) by Vanderbilt DRTC lipid core. Catecholamines were measured using HPLC separation with electrochemical detection.
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Calculations
Whole-body glucose uptake (M BW in mg/kg per minute), an index of maximal muscle glucose use, was calculated as the average amount of glucose infused during the last 30 minutes of the clamp.
14 Lean body mass (LBM, in kilograms), obtained from DEXA scans, was used to adjust M (M LBM ). A cutoff value of 5.2 mg/kg per minute during the intact day was used to define insulin sensitive (>5.2 mg/kg per minute) or resistant subjects (<5.2 mg/kg per minute). 25 
Statistical Analysis
Data are presented as mean±SEM. Comparisons of outcomes by intervention within subjects were performed using Wilcoxon signed-rank nonparametric tests. The main outcome was insulin sensitivity measured as the glucose infusion rate corrected by body weight (M BW , mg/ kg per minute, higher number indicating greater insulin sensitivity) needed to maintain euglycemia during the last 30 minutes of the hyperinsulinemic clamp. The null hypothesis was that insulin sensitivity would not be different between intact and blocked study days among insulin-resistant subjects. All of the tests were 2-tailed, and a P value of <0.05 was considered significant. Analyses were performed with SPSS statistical software (version 22.0.0; SPSS Inc). Power calculations estimated that 13 subjects were needed to detect a difference in glucose use of 1.7 mg/kg per minute between the intact and the blocked days, with 90% power, assuming a SD of 1.7, and a type I error probability of 5%.
Results
We enrolled 21 subjects with a mean age of 43±2.3 years. As expected, they were obese with a body mass index of 35±2.2 kg/m 2 and 41.5±1.7% of body fat. Most of them were also prehypertensive or had hypertension (139/85±4/3 mm Hg). On the basis of euglycemic clamp data from the saline day, we divided subjects into insulin-sensitive subjects (M BW ≥5; n=7) or resistant (M BW <5; n=14). Baseline data obtained during the screening visit and during the study days are presented in Table 1 . Insulin-resistant subjects were more obese and had higher plasma glucose and insulin levels. Figure 2 shows basal MSNA for the 5 insulin-sensitive and 6 insulin-resistant subjects in whom this data were available. The remaining subjects declined to participate in the MSNA portion of the study (n=7) or a satisfactory recording could not be obtained (n=3). MSNA was higher among insulin-resistant subjects than in insulin-sensitive subjects (23.3±1.5 versus17.2±2.1 burst/min; P=0.03).
Hemodynamic data obtained on both study days are shown in Table 2 . During the saline study day (intact autonomic function), insulin produced a small increase in HR in both insulin-sensitive and insulin-resistant subjects; it also increased plasma epinephrine levels, but this increase only reached statistical significance in insulin-resistant subjects. None of the subjects developed hypoglycemia (plasma glucose, >70 mg/ Values are expressed as mean±SEM and were obtained during the screening visit, except for those marked with *, which were the average at baseline of the 2 study days. %B indicates beta cell function; %S, insulin sensitivity; BMI, body mass index; BP, blood pressure; F/T, female/total; HDL, highdensity lipoprotein; HFRRI, high frequency variability of heart rate; HOMA2, homeostatic model; hsCRP, high sensitivity C reactive protein; IR, insulin resistance; LDL, low-density lipoprotein; LF RRI , low-frequency variability of heart rate; and LF SYS , low-frequency variability of systolic BP.
by guest on July 12, 2017 http://hyper.ahajournals.org/ Downloaded from dL) at any point during any of the clamps. Furthermore, during the last 30 minutes of the clamp, when blood was drawn for catecholamines, plasma glucose levels were ≥90 mg/dL in all subjects. During the autonomic blockade study day, HR increased significantly as expected, reflecting net vagal withdrawal, and all indices of autonomic function decreased, including plasma norepinephrine, LF SYS and HF RRI , in both insulin-sensitive and insulin-resistant subjects. Ganglionic blockade also prevented the increase in plasma epinephrine induced by insulin in insulin-resistant subjects.
Metabolic data obtained on both study days are shown in Table 3 . During the saline study day (intact autonomic function), hyperinsulinemia resulted in a decrease in glucagon and in free fatty acids, in both insulin-sensitive and insulin-resistant subjects. These changes were also apparent during the autonomic blockade study day. When comparing values during the clamp between autonomic blockade and saline days, autonomic blockade resulted in higher free fatty acids plasma values but only in the insulin-sensitive subjects (0.06±0.01 versus 0.11±0.06 mmol/L; P=0.039).
There were no differences in insulin sensitivity between intact and blocked study days in insulin sensitive subjects (M BW , 6.9±0.8 and 6.5±0.9 mg/kg per minute for the intact and blocked days, respectively; P=0.310). In contrast, in insulinresistant subjects, autonomic blockade significantly improved insulin sensitivity (M BW from 3.1±0.3-3.8±0.3 mg/kg per minute; P=0.025; Figure 3) . A similar result was obtained if values were adjusted by lean body mass (M LBM , from 5.4±0.6 to 6.6±0.6 mg/kg of lean body mass/min; P=0.030). Values are expressed as mean±SEM. The P (clamp) column reflects differences between study days (saline vs blocked) during the clamp. No significant differences were observed between study days at baseline. CO indicates cardiac output; DBP, diastolic blood pressure; HF RRI , high-frequency variability of HR; HR, heart rate; LF RRI , low-frequency variability of HR, LF SYS , low-frequency variability of systolic blood pressure; SBP, systolic blood pressure; SV, stroke volume; and TPR, total peripheral resistance. *P<0.05 for the comparison between baseline and clamp for each study day. 
Discussion
The main finding in this study is that sympathetic activity was higher in insulin-resistant obese subjects when compared with insulin-sensitive subjects, and that autonomic withdrawal acutely improved insulin sensitivity in insulin-resistant patients, as determined by the hyperinsulinemic euglycemic clamp method. We interpret these findings as supporting the notion that sympathetic activation contributes to the metabolic abnormalities associated with obesity. They also raise the possibility of a negative feedback loop, whereby the increased sympathetic activity contributes to insulin resistance, leading to a compensatory increase in insulin levels, which then contribute to greater sympathetic activation. Consistent with this possibility, the improvement in insulin sensitivity produced by pioglitazone is associated with lowering of sympathetic activity. 26 Most studies have shown that obesity is accompanied by an increase in sympathetic tone. Furthermore, total fat mass and more specifically visceral fat mass are positively correlated with measurements of sympathetic activity. 27 Our results are in agreement with these reports because our insulin-resistant subjects, who had increased sympathetic activity, also had higher levels of fat mass and a greater waist/hip ratios, suggesting greater visceral fat. They also had higher insulin and lower adiponectin levels, 2 pathways proposed to contribute to sympathetic activation in obesity. 27, 28 The sympathetic activation in obesity, however, is not homogenous. It is often not reflected in forearm venous plasma norepinephrine but is preferentially increased in sympathetic fibers relevant to BP regulation, as evidenced by an increase MSNA, which reflects central sympathetic outflow coupled to baroreflex regulation. 29 There is an increasing evidence that this sympathetic activation contributes to hypertension in obesity. We have previously shown, using the same ganglionic blockade approach used in this study, that autonomic withdrawal normalizes BP in obese hypertensives. 30 Intrinsic systolic BP (in the absence of autonomic influences) decreased to normal levels in obese hypertensives (106±4.6 mm Hg), consistent with the hypothesis that sympathetic activation contributes to hypertension in obesity. However, sympathetic activation is unlikely the sole determinant of the increase in BP associated with obesity because intrinsic BP was still 15 mm Hg higher than normotensive controls (91±2.2 mm Hg). 30 Less is known about the contribution of sympathetic activation to the metabolic abnormalities of obesity. It has been proposed that sympathetic activation is a compensatory homeostatic attempt to increase resting metabolic rate and restore energy balance. Resting metabolic rate is indeed consistently higher in obese individuals, but we previously found that ganglionic blockade decreased resting energy expenditure by the same percentage (≈3%) in obese and lean individuals, so that resting energy expenditure in obese individuals remained elevated after ganglionic blockade. 31 This suggests that sympathetic activation failed to provide the expected beneficial metabolic effect on resting energy expenditure. Furthermore, the increase in resting energy expenditure seen in obesity could be explained completely by the increase in fat free mass that accompanies weight gain. 31 Collectively, these findings suggest that the sympathetic activation in obesity contributes to hypertension but has no benefit on metabolic function. On the contrary, we hypothesized that sympathetic activation has a negative metabolic effect, contributing to insulin resistance.
Indeed, we found that ganglionic blockade selectively improves insulin sensitivity in patients who are insulin resistant but has no effect in those who are insulin sensitive. Insulin sensitivity was determined using the hyperinsulinemic euglycemic clamp, which is considered the gold standard. On the basis of these findings, we propose that sympathetic activation contributes to the insulin resistance of obesity. In agreement with our findings, previous studies showed that an acute increase in sympathetic nerve activity results in reduced forearm glucose uptake in healthy lean controls. 8 We propose that the improvement in glucose utilization during autonomic blockade is best explained by an improvement in muscle glucose uptake, rather than changes in hepatic glucose production. This interpretation is based on our use of an insulin infusion rate that is high enough to suppress hepatic glucose production. Definitive proof will require the use of isotopes to confirm suppression of glucose production and to measure endogenous glucose production, which is particularly important in insulin-resistant subjects and even in subjects with impaired fasting glucose. 32 The mechanism by which sympathetic activation would impair insulin-mediated glucose uptake 8 is not completely understood. Adrenergic receptors can inhibit insulin-mediated glucose uptake in target tissue, such as skeletal muscle, 33 but it is not clear how important this mechanism is during normal situations or during the conditions of our study (hyperinsulinemic clamps). Insulin sensitivity is also modulated by glucagon and hormonal factors, but we did not observe significant differences between intact and blocked days in a variety of metabolic indices measured during the euglycemic clamp (Table 3 , insulinresistant group). Therefore, it is unlikely that changes in any of these hormones explain the improvement in insulin sensitivity. Insulin sensitivity is also affected by blood flow, and sympathetically mediated vasoconstriction may impair insulin sensitivity through this mechanism. 34 Conversely, insulin induces nitric oxide-mediated vasodilation, which increases substrate delivery to the muscle, to promote glucose uptake and thus improve insulin sensitivity. 35 This effect is more important in the microvasculature, and insulin-induced vasodilation is hemodynamically not apparent in subjects with an intact autonomic nervous system because of baroreflex buffering of BP. In contrast, insulin administration substantially lowers BP in patients with autonomic failure. 36 Therefore, we were concerned that insulin would lower BP when infused during ganglionic blockade. This could create both a safety concern and would also complicate the interpretation of our results. For this reason, we decided to clamp BP with the NOS inhibitor N-monomethyl-L-arginine while infusing insulin during autonomic blockade. Using this approach, we were successful in matching BP on each study day during the last 30 minutes of the clamp, when insulin sensitivity was measured. It is noteworthy that we observed an improvement of insulin sensitivity even in the presence of NOS inhibition, which can reduce glucose uptake. 35, 37 In the present study, however, we did not try to achieve complete NOS inhibition but only to counteract any decrease in BP produced by insulin in the presence of ganglionic blockade. Although we effectively clamped BP during our studies, it is possible that sympathetic withdrawal improved blood flow at the level of the microcirculation and improved insulin sensitivity through this mechanism. 38 We should note that ganglionic blockade produces complete suppression of both sympathetic and parasympathetic activities. Parasympathetic stimulation has beneficial metabolic effects, 39 so parasympathetic suppression is less likely to explain the improved sensitivity to insulin during ganglionic blockade. A direct vasodilatory effect of ganglionic blockade has been reported in animal studies, [40] [41] [42] but in the absence of other vasodilators, trimethaphan does not lower BP in normal subjects below the intrinsic BP range and does not lower BP in patients with pure autonomic failure. 43 It is unlikely, therefore, that a direct vasodilating action of trimethaphan played a role in the responses observed in the present study.
In summary, these findings suggest that sympathetic activation contributes to impaired glucose utilization and insulin resistance in obesity, thus supporting the concept that sympathetic activation contributes to the cardiovascular and metabolic derangements associated with obesity. This is also consistent with the existence of a negative feedback loop whereby the increase in insulin levels that accompanies insulin resistance contributes to sympathetic activation, leading to further insulin resistance.
Perspectives
Obesity has become the most common underlying condition associated with hypertension. Our findings would imply that therapies that lower sympathetic tone would be preferable in the treatment of obesity hypertension. Uncontrolled studies suggest that newer sympatholytics (ie, moxonidine) improve insulin sensitivity 44 but are not widely used or available. It has been suggested that renal denervation improved insulin sensitivity, 45 but its overall effectiveness in reducing sympathetic tone, 46 or treating hypertension, 47 remains unclear. However, thiazides, which are recommended as first-line therapy for hypertension, increase in sympathetic activity 48 and increase the risk of developing diabetes mellitus. These recommendations, however, are based on outcome trials that enrolled patients that were older and less obese than the vast majority of obese hypertensives seen in clinical practice. 49 It is not clear, therefore, that thiazides should be the initial choice for starting antihypertensive therapy in such patients. Individual differences in insulin sensitivity were measured on the intact and blocked autonomic study days in the insulin-resistant obese subjects. M BW , a measure of the glucose infusion rate needed to maintain euglycemia corrected by plasma glucose and body weight was significantly higher on the blocked when compared with intact study day, suggesting increased insulin sensitivity after acute autonomic blockade. 
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